Differences in psychometric properties, cut-off scores, and outcomes between the Barthel Index and Modified Rankin Scale in pharmacotherapy-based stroke trials: Systematic literature review

Current Medical Research and Opinion

Volumn 25, Issue 6, 2009, Pages 1329-1341

  Balu, Sanjeev ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Barthel index; Cerebrovascular disease; Modified rankin scale; Randomized clinical trials; Stroke; Utilities

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ALTEPLASE; CLOMETHIAZOLE; CLOPIDOGREL; DAPSONE; DESMOTEPLASE; DISUFENTON SODIUM; ERYTHROPOIETIN; FLUNARIZINE; HUMAN TISSUE UROKINASE TYPE PLASMINOGEN ACTIVATOR; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; LANICEMINE; LUBELUZOLE; MINOCYCLINE; TELMISARTAN; UNCLASSIFIED DRUG; UROKINASE; VINPOCETINE;

BARTHEL INDEX; CLINICAL TRIAL; DISABILITY; DISEASE SEVERITY; FOLLOW UP; GLASGOW COMA SCALE; HUMAN; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PSYCHOMETRY; RANKIN SCALE; REVIEW; SENSITIVITY AND SPECIFICITY; STROKE; STROKE PATIENT; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

CENTRAL NERVOUS SYSTEM AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY; HEALTH STATUS INDICATORS; HUMANS; PROGNOSIS; PSYCHOLOGICAL TECHNIQUES; PSYCHOMETRICS; REFERENCE VALUES; RESEARCH DESIGN; STROKE; TREATMENT OUTCOME;

EID: 67649450097     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902875877     Document Type: Review

References (51)

1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997;349:1269-1276 (Pubitemid 27192468)
2. American Stroke Association, Statistics 2006. Available at http://www.americanheart.org/downloadable/heart/1140534985281Statsupdate06book. pdf [Last accessed 10 December 2008]
3. Mahoney FI, Barthel DW. Functional evaluation: The Barthel Index. Maryland State Med J 1965;14:61-65
4. Collin C, Wade D. The Barthel Index: a reliability study. Int Disabil Stud 1988;10:61-63 (Pubitemid 18159441)
5. Rankin J. Cerebral vascular accidents in patients over the age of 60: II. Prognosis. Scot Med J 1957;2:200-215
6. Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-607 (Pubitemid 18126965)
7. Kwon S, Hartzema AG, Duncan PW, et al. Disability measures in stroke. Relationship among the Barthel Index, the Functional Independence Measure, and the Modified Rankin Scale. Stroke 2004;35:918-923
8. Dromerick AW, Edwards DF, Diringer MN. Sensitivity to changes in disability after stroke: a comparison of four scales useful in clinical trials. J Rehabil Res Dev 2003;40:1-8 (Pubitemid 36337060)
9. Weimar C, Kurth T, Kraywinkel K, et al. Assessment of functioning and stability after ischemic stroke. Stroke 2002;33:2053-2059 (Pubitemid 34840067)
10. Wolfe CDA, Taub NA, Woodrow EJ, et al. Assessment of scales of disability and handicap for stroke patients. Stroke 1991;22:1242-1244
11. Duncan PW, Jorgensen HS, Wade DT. Outcome measures in acute stroke trials. A systematic review and some recommendations to improve practice. Stroke 2000;31:1429-1438
12. Gosman-Hedstrom G, Svensson E. Parallel reliability of the functional independence measure and the Barthel ADL index. Disabil Rehabil. 2000;22:702-715 (Pubitemid 30950104)
13. Clark WM, Wissman S, Albers GW, et al. Recombinant tissuetype plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999;282:2019-2026
14. Feigin VL, Doronin BM, Popova TF, et al. Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial. Eur J Neurol. 2001;8:81-85 (Pubitemid 32154579)
15. Hacke W, Kaste M, Fieschi C, et al. for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-1025
16. Diener HC. Multinational randomised controlled trial of lubeluzole in acute ischaemic stroke. Cerebrovasc Dis. 1998;8:172-181 (Pubitemid 28192819)
17. Franke CL, Palm R, Dalby M, et al. Flunarizine in stroke treatment (FIST): a double-blind, placebo-controlled trial in Scandinavia and the Netherlands. Acta Neurol Scand 1996;93:56-60 (Pubitemid 26033957)
18. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8:495-505 (Pubitemid 36337492)
19. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study GroupTissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587
20. Steiner T, Bluhmki E, Kaste M, et al. for the ECASS Study Group. The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification. Cerebrovasc Dis 1998;8:198-203
21. Lyden P, Shuaib A, Ng K, et al. on behalf of the CLASS-I/H/T Investigators. Clomethiazole acute stroke study in ischemic stroke (CLASS-I). Stroke 2002;33:122-128
22. Lees KR, Zivin JA, Ashwood T, et al. for the Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. NXY-059 for acute ischemic stroke. N Eng J Med. 2006;354:588-600
23. Hacke W, Albers G, Al-Rawi Y, et al. for the DIAS Study Group. The desmoteplase in acute ischemic stroke trial (DIAS). A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66-73
24. The Abiciximab in Ischemic Stroke InvestigatorsAbciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study. Stroke 2000;31:601-609
25. Clark WM, Albers GW, Madden KP, Hamilton S, for the Thrombolytic Therapy in Acute Ischemic Stroke Study Investigators. The rtPA (Alteplase) 0- to 6-hour acute stroke trial, part A (A0276g). Stroke 2000;31:811-816
26. Lees KR, Dyker AG, Sharma A, et al. Tolerability of the low-affinity, use-dependent NMDA antagonist AR-R15896AR in stroke patients. A dose-ranging study. Stroke 2001;32:466-472 (Pubitemid 32155236)
27. Lewandowski CA, Frankel M, Tomsick TA, et al. and the EMS Bridging Trial Investigators. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke. Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999;30:2598-2605
28. Diener HC, Cortens M, Ford G, et al. on behalf of the LUB-INT-13 Investigators. Lubeluzole in acute ischemic stroke treatment. A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. Stroke 2000;31:2543-2551
29. Kwiatkowski TG, Libman RB, Frankel M, et al. for the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Eng J Med 1999;340:1781-1787
30. Enlimomab Acute Stroke Trial Investigators. Use of anti-ICAM-1 therapy in ischemic stroke. Results of the Enlimomab acute stroke trial. Neurology 2001;57:1428-1434
31. Ogawa A, Mori E, Minematsu K, et al. For The MELT Japan Study Group. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: The Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) Japan. Stroke 2007;38:2633-2639
32. Diener H-C, Sacco RL, Yusuf S, et al. For the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind,active and placebo-controlled study. Lancet Neurol 2008;7:875-884
33. Chao AC, Teng MM, Chung CP, et al. Preliminary efficacy report of a novel thrombolytic agent for acute ischaemic stroke within a 5-hour window. CNS Drugs 2007;21:937-946 (Pubitemid 47557107)
34. Lampl Y, Boaz M, Gilad R, et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 2007;69:1404-1410 (Pubitemid 47511461)
35. Nader-Kawachi J, Gongora-Rivera F, Santos-Zambrano J, et al. Neuroprotective effect of dapsone in patients with acute ischemic stroke: a pilot study. Neurol Res 2007;29:331-334 (Pubitemid 46802373)
36. Lyden PD, Shuaib A, Lees KR, et al. Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the CHANT trial. Stroke 2007;38:2262-2269 (Pubitemid 47457566)
37. Granger CV, Devis LS, Peters MC, et al. Stroke rehabilitation: analysis of repeated Barthel index measures. Arch Phys Med Rehabil. 1979;60:14-17 (Pubitemid 9101111)
38. Kay R, Wong KS, Perez G, et al. Dichotomizing stroke outcomes based on self-reported dependency. Neurology 1997;49:1694-1696 (Pubitemid 28015140)
39. Uyttenboogaart M, Stewart RE, Vroomen PCAJ, et al. Optimizing cutoff scores for the Barthel index and the modified Rankin scale for defining outcome in acute stroke trials. Stroke 2005;36:1984-1987 (Pubitemid 41266538)
40. Celani MG, Cantisani TA, Righetti E, et al. on behalf of the Italian International Stroke Trial (IST) Collaborators. Different measures for assessing stroke outcome. An analysis from the International Stroke Trial in Italy. Stroke 2002;33:218-223
41. Sulter G, Steen C, Keyser JD. Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke 1999;30:1538-1541 (Pubitemid 29379599)
42. Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol 2004;61:1066-1070 (Pubitemid 38915948)
43. Guyatt GH, Juniper EF, Walter SD, et al. Interpreting treatment effects in randomised trials. BMJ 1998;316:690-693 (Pubitemid 28121037)
44. Walter SD. Number needed to treat (NNT): estimation of a measure of clinical benefit. Stat Med 2001;20:3947-3962 (Pubitemid 34030948)
45. Young FB, Lees KR, Weir CJ, for the Glycine Antagonist in Neuroprotection (GAIN) International Trial Steering Committee and Investigators. Strengthening acute stroke trials through optimal use of disability end points. Stroke 2003;34:2676-2680
46. Lees KR. Neuroprotection is unlikely to be effective in humans suing current trial designs: an opposing view. Stroke 2002;33:308-309 (Pubitemid 34052233)
47. Berge E, Barer D. Could stroke trials be missing important treatment effects? Cerebrovasc Dis 2002;13:73-75
48. Tilley BC, Marler J, Geller NL, et al. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial. Stroke 1996;27:2136-2142 (Pubitemid 26372593)
49. Weir CJ, Kaste M, Lees KR, for the Glycine Antagonist in Neuroprotection (GAIN) International Trial Steering Committee and Investigators. Targeting neuroprotection clinical trials to ischemic stroke patients with potential to benefit from therapy. Stroke 2004;35:2111-2116
50. New PW, Buchbinder R. Critical appraisal and review of the Rankin scale and its derivatives. Neuroepidemiology 2006;26:4-15 (Pubitemid 41797932)
51. Kasner SE. Clinical interpretation and use of stroke scales. Lancet Neurol 2006;5:603-612 (Pubitemid 43867434)